Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Mar 1;101(5):1163–1174. doi: 10.1172/JCI992

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.

C Wahl 1, S Liptay 1, G Adler 1, R M Schmid 1
PMCID: PMC508669  PMID: 9486988

Abstract

Transcription factors of the NF-kappaB/Rel family are critical for inducible expression of multiple genes involved in inflammatory responses. Sulfasalazine and its salicylate moiety 5-aminosalicylic acid are among the most effective agents for treating inflammatory bowel disease and rheumatoid arthritis. However, the mode of action of these drugs remains unclear. Here we provide evidence that the transcription factor NF-kappaB is a target of sulfasalazine-mediated immunosuppression. Treatment of SW620 colon cells with sulfasalazine inhibited TNFalpha-, LPS-, or phorbol ester- induced NF-kappaB activation. NF-kappaB-dependent transcription was inhibited by sulfasalazine at micro- to millimolar concentrations. In contrast, 5-aminosalicylic acid or sulfapyridine did not block NF-kappaB activation at all doses tested. TNFalpha-induced nuclear translocation of NF-kappaB was prevented by sulfasalazine through inhibition of IkappaBalpha degradation. When blocking proteasome-mediated degradation of IkappaBalpha, we could demonstrate that sulfasalazine interfered with IkappaBalpha phosphorylation, suggesting a direct effect on an IkappaBalpha kinase or on an upstream signal. Inhibition of NF-kappaB activation seems to be specific since other DNA-binding activities such as AP1 were not affected. These results demonstrate that sulfasalazine is a potent and specific inhibitor of NF-kappaB activation, and thus may explain some of the known biological properties of sulfasalazine.

Full Text

The Full Text of this article is available as a PDF (538.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aruoma O. I., Wasil M., Halliwell B., Hoey B. M., Butler J. The scavenging of oxidants by sulphasalazine and its metabolites. A possible contribution to their anti-inflammatory effects? Biochem Pharmacol. 1987 Nov 1;36(21):3739–3742. doi: 10.1016/0006-2952(87)90028-1. [DOI] [PubMed] [Google Scholar]
  2. Auphan N., DiDonato J. A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995 Oct 13;270(5234):286–290. doi: 10.1126/science.270.5234.286. [DOI] [PubMed] [Google Scholar]
  3. Azad Khan A. K., Piris J., Truelove S. C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977 Oct 29;2(8044):892–895. doi: 10.1016/s0140-6736(77)90831-5. [DOI] [PubMed] [Google Scholar]
  4. Baeuerle P. A., Baltimore D. NF-kappa B: ten years after. Cell. 1996 Oct 4;87(1):13–20. doi: 10.1016/s0092-8674(00)81318-5. [DOI] [PubMed] [Google Scholar]
  5. Beg A. A., Finco T. S., Nantermet P. V., Baldwin A. S., Jr Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol Cell Biol. 1993 Jun;13(6):3301–3310. doi: 10.1128/mcb.13.6.3301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bird H. A. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis? Br J Rheumatol. 1995 Nov;34 (Suppl 2):16–19. [PubMed] [Google Scholar]
  7. Brown K., Gerstberger S., Carlson L., Franzoso G., Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science. 1995 Mar 10;267(5203):1485–1488. doi: 10.1126/science.7878466. [DOI] [PubMed] [Google Scholar]
  8. Carlin G., Djursäter R., Smedegård G. Inhibitory effects of sulfasalazine and related compounds on superoxide production by human polymorphonuclear leukocytes. Pharmacol Toxicol. 1989 Aug;65(2):121–127. doi: 10.1111/j.1600-0773.1989.tb01141.x. [DOI] [PubMed] [Google Scholar]
  9. Chiao P. J., Miyamoto S., Verma I. M. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):28–32. doi: 10.1073/pnas.91.1.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  11. Das K. M., Eastwood M. A., McManus J. P., Sircus W. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973 Aug;14(8):631–641. doi: 10.1136/gut.14.8.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Duckett C. S., Perkins N. D., Kowalik T. F., Schmid R. M., Huang E. S., Baldwin A. S., Jr, Nabel G. J. Dimerization of NF-KB2 with RelA(p65) regulates DNA binding, transcriptional activation, and inhibition by an I kappa B-alpha (MAD-3). Mol Cell Biol. 1993 Mar;13(3):1315–1322. doi: 10.1128/mcb.13.3.1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Frantz B., O'Neill E. A. The effect of sodium salicylate and aspirin on NF-kappa B. Science. 1995 Dec 22;270(5244):2017–2019. doi: 10.1126/science.270.5244.2017. [DOI] [PubMed] [Google Scholar]
  14. Fujiwara M., Mitsui K., Yamamoto I. Inhibition of proliferative responses and interleukin 2 productions by salazosulfapyridine and its metabolites. Jpn J Pharmacol. 1990 Oct;54(2):121–131. doi: 10.1254/jjp.54.121. [DOI] [PubMed] [Google Scholar]
  15. Gaginella T. S., Walsh R. E. Sulfasalazine. Multiplicity of action. Dig Dis Sci. 1992 Jun;37(6):801–812. doi: 10.1007/BF01300376. [DOI] [PubMed] [Google Scholar]
  16. Gionchetti P., Guarnieri C., Campieri M., Belluzzi A., Brignola C., Iannone P., Miglioli M., Barbara L. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci. 1991 Feb;36(2):174–178. doi: 10.1007/BF01300752. [DOI] [PubMed] [Google Scholar]
  17. Hoult J. R. Pharmacological and biochemical actions of sulphasalazine. Drugs. 1986;32 (Suppl 1):18–26. doi: 10.2165/00003495-198600321-00005. [DOI] [PubMed] [Google Scholar]
  18. Ito C. Y., Kazantsev A. G., Baldwin A. S., Jr Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res. 1994 Sep 11;22(18):3787–3792. doi: 10.1093/nar/22.18.3787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Klotz U., Maier K., Fischer C., Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med. 1980 Dec 25;303(26):1499–1502. doi: 10.1056/NEJM198012253032602. [DOI] [PubMed] [Google Scholar]
  20. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994 Aug 12;265(5174):956–959. doi: 10.1126/science.8052854. [DOI] [PubMed] [Google Scholar]
  21. MacDermott R. P., Schloemann S. R., Bertovich M. J., Nash G. S., Peters M., Stenson W. F. Inhibition of antibody secretion by 5-aminosalicylic acid. Gastroenterology. 1989 Feb;96(2 Pt 1):442–448. doi: 10.1016/0016-5085(89)91569-2. [DOI] [PubMed] [Google Scholar]
  22. Neurath M. F., Pettersson S., Meyer zum Büschenfelde K. H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996 Sep;2(9):998–1004. doi: 10.1038/nm0996-998. [DOI] [PubMed] [Google Scholar]
  23. Omary M. B., de Grandpre L., McCaffrey M., Kagnoff M. F. Biochemical and morphological differentiation of the human colonic epithelial cell line SW620 in the presence of dimethylsulfoxide. J Cell Biochem. 1992 Mar;48(3):316–323. doi: 10.1002/jcb.240480312. [DOI] [PubMed] [Google Scholar]
  24. Palombella V. J., Rando O. J., Goldberg A. L., Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994 Sep 9;78(5):773–785. doi: 10.1016/s0092-8674(94)90482-0. [DOI] [PubMed] [Google Scholar]
  25. Peppercorn M. A., Goldman P. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973 Feb;64(2):240–245. [PubMed] [Google Scholar]
  26. Pierce J. W., Read M. A., Ding H., Luscinskas F. W., Collins T. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol. 1996 May 15;156(10):3961–3969. [PubMed] [Google Scholar]
  27. Rhodes J. M., Bartholomew T. C., Jewell D. P. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut. 1981 Aug;22(8):642–647. doi: 10.1136/gut.22.8.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Riis P., Anthonisen P., Wulff H. R., Folkenborg O., Bonnevie O., Binder V. The prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol. 1973;8(1):71–74. [PubMed] [Google Scholar]
  29. Romano M. F., Lamberti A., Petrella A., Bisogni R., Tassone P. F., Formisano S., Venuta S., Turco M. C. IL-10 inhibits nuclear factor-kappa B/Rel nuclear activity in CD3-stimulated human peripheral T lymphocytes. J Immunol. 1996 Mar 15;156(6):2119–2123. [PubMed] [Google Scholar]
  30. Rubinstein A., Das K. M., Melamed J., Murphy R. A. Comparative analysis of systemic immunological parameters in ulcerative colitis and idiopathic proctitis: effects of sulfasalazine in vivo and in vitro. Clin Exp Immunol. 1978 Aug;33(2):217–224. [PMC free article] [PubMed] [Google Scholar]
  31. Scheinman R. I., Cogswell P. C., Lofquist A. K., Baldwin A. S., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995 Oct 13;270(5234):283–286. doi: 10.1126/science.270.5234.283. [DOI] [PubMed] [Google Scholar]
  32. Schenk H., Klein M., Erdbrügger W., Dröge W., Schulze-Osthoff K. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappa B and AP-1. Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1672–1676. doi: 10.1073/pnas.91.5.1672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schmid R. M., Liptay S., Betts J. C., Nabel G. J. Structural and functional analysis of NF-kappa B. Determinants of DNA binding specificity and protein interaction. J Biol Chem. 1994 Dec 23;269(51):32162–32167. [PubMed] [Google Scholar]
  34. Schmid R. M., Perkins N. D., Duckett C. S., Andrews P. C., Nabel G. J. Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. Nature. 1991 Aug 22;352(6337):733–736. doi: 10.1038/352733a0. [DOI] [PubMed] [Google Scholar]
  35. Schmidt K. N., Amstad P., Cerutti P., Baeuerle P. A. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. Chem Biol. 1995 Jan;2(1):13–22. doi: 10.1016/1074-5521(95)90076-4. [DOI] [PubMed] [Google Scholar]
  36. Schreck R., Meier B., Männel D. N., Dröge W., Baeuerle P. A. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992 May 1;175(5):1181–1194. doi: 10.1084/jem.175.5.1181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schreck R., Rieber P., Baeuerle P. A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991 Aug;10(8):2247–2258. doi: 10.1002/j.1460-2075.1991.tb07761.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Schuerer-Maly C. C., Eckmann L., Kagnoff M. F., Falco M. T., Maly F. E. Colonic epithelial cell lines as a source of interleukin-8: stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology. 1994 Jan;81(1):85–91. [PMC free article] [PubMed] [Google Scholar]
  39. Sheldon P., Webb C., Grindulis K. A. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action? Br J Rheumatol. 1988 Oct;27(5):344–349. doi: 10.1093/rheumatology/27.5.344. [DOI] [PubMed] [Google Scholar]
  40. Siebenlist U., Franzoso G., Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405–455. doi: 10.1146/annurev.cb.10.110194.002201. [DOI] [PubMed] [Google Scholar]
  41. Sutherland L. R., May G. R., Shaffer E. A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993 Apr 1;118(7):540–549. doi: 10.7326/0003-4819-118-7-199304010-00009. [DOI] [PubMed] [Google Scholar]
  42. Taggart A. J., Neumann V. C., Hill J., Astbury C., Le Gallez P., Dixon J. S. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis? Drugs. 1986;32 (Suppl 1):27–34. doi: 10.2165/00003495-198600321-00006. [DOI] [PubMed] [Google Scholar]
  43. Takeshita S., Gage J. R., Kishimoto T., Vredevoe D. L., Martínez-Maza O. Differential regulation of IL-6 gene transcription and expression by IL-4 and IL-10 in human monocytic cell lines. J Immunol. 1996 Apr 1;156(7):2591–2598. [PubMed] [Google Scholar]
  44. Thompson J. E., Phillips R. J., Erdjument-Bromage H., Tempst P., Ghosh S. I kappa B-beta regulates the persistent response in a biphasic activation of NF-kappa B. Cell. 1995 Feb 24;80(4):573–582. doi: 10.1016/0092-8674(95)90511-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES